Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor
- 1 February 1997
- journal article
- review article
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 71 (2) , 173-179
- https://doi.org/10.1016/s0301-2115(96)02630-9
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancyZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Overexpression of the Oncogene c-erb B2 in Primary Ovarian CancerInternational Journal of Gynecological Pathology, 1994
- The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot studyEuropean Journal Of Cancer, 1993
- Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- c‐erbB‐2 oncogene expression in ovarian cancerThe Journal of Pathology, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- The Molecular Genetics of CancerScience, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985